How Much Money Are At-Home Covid-19 Tests Bringing In?
Eight of essentially the most distinguished check makers are navigating a whiplash market.
As the Omicron wave of the pandemic swept throughout America this winter, makers of at-home Covid checks confronted a novel enterprise dilemma. Seemingly in a single day, demand for his or her merchandise turned infinite. Huge authorities contracts have been up for grabs. By mid-January, the Biden administration had promised to purchase 1 billion of the checks. However it was nearly equally sure that demand for the checks would vanish—not less than quickly—by the point spring arrived.
Sunnyvale, California-based iHealth Labs, which solely acquired FDA authorization for its check in November, churned out greater than 500 million Covid-19 house check kits for the U.S. market in February an astronomical enhance over the 20-to-30 million it produced in December. “We cranked up in a short time,” says iHealth chief working officer Jack Feng. “It was nearly like a battle.”
It was a complete new line of enterprise for iHealth, which is majority-owned by China’s publicly traded Andon Well being and made stuff like blood-pressure displays and thermometers earlier than the pandemic. Its contract producer in Tianjin, China, additionally owned by Andon, made kits round the clock, and even stayed open with partial employees on Chinese language New Yr’s. To assist get the checks to the States, iHealth chartered 100 airplanes. Some 350 million of its antigen checks went to satisfy its authorities contracts, that are price greater than $1.3 billion, with the remaining going to drugstores and different retailers.
“I feel we offered extra checks than the opposite check makers in complete [in February]. Greater than half within the U.S. market have been produced by us,” Feng says. “To start with we thought, we’re only a small man and there are some massive guys which are a lot, a lot larger than us….We didn’t anticipate we will be the most important drive to produce this check.”
“The way forward for the Covid at-home testing market will not help 16 or extra merchandise.”
iHealth is only one of many firms which have rushed to provide house checks. To this point, the FDA has authorized 16 home tests, together with 13 fast antigen checks and three molecular ones, from large firms and startups alike. Abbott, the $43 billion (2021 gross sales) goliath, constructed crops in Maine and Illinois to churn out its well-liked BinaxNow check. To this point, it has distributed greater than 1.4 billion Covid checks. San Diego-based Quidel says Covid-19 merchandise, together with its QuickVue check, accounted for round $1.3 billion of its $1.7 billion in income final yr.
However coping with the uncertainties of demand hasn’t been simple. Final summer season, as virus instances fell, Abbott discarded test cards utilized in its house checks and laid off staff, solely to rehire them within the fall. Now that the newest Omicron wave has handed, testing firms might want to work out learn how to plan for a enterprise the place demand is available in suits and begins—and the place retail costs are below strain.
“If we’ve got seen the worst that Covid has in retailer for us, given the lackluster help by the CDC for house testing and the present degree of Covid fatigue, it appears protected to imagine that the way forward for the Covid at-home testing market gained’t help 16 or extra merchandise,” says Michael Abrams, managing companion of St. Louis-based healthcare consultancy Numerof & Associates.
Here is how eight of essentially the most distinguished at-home check makers are faring:
Abbot Laboratories
TEST: BinaxNow (antigen)
MARKET CAP (ticker: ABT): $201 billion
PANDEMIC STOCK PERFORMANCE: Up 46%
REVENUE: $43 billion
FINANCIAL IMPACT OF COVID: Abbott’s gross sales associated to Covid testing, together with BinaxNow, reached $7.7 billion in 2021, almost double the earlier yr’s $3.9 billion.
WHAT THEY’VE DONE: Distributed greater than 1.4 billion Covid-19 checks for the reason that begin of the pandemic. Constructed manufacturing crops in Maine and Illinois.
WHAT THEY PLAN TO DO: Crank up manufacturing from 70 million checks monthly in January towards 100 million in March.
KEY QUOTE: “I feel the larger image right here is, clearly….testing will finally ramp down, however there will likely be a portion that will likely be sustained,” CEO Robert Ford mentioned on the JP Morgan well being care convention in January.
Becton Dickinson
TEST: BD Veritor (antigen)
MARKET CAP (ticker: BDX): $72 billion
PANDEMIC STOCK PERFORMANCE: Up 10%
REVENUE: $20 billion
FINANCIAL IMPACT OF COVID: Covid-19 income anticipated to succeed in $450 million this yr, with the vast majority of it within the first half, in accordance with a report by analysts at William Blair.
WHAT THEY’VE DONE: Developed a digital strategy to studying check outcomes that will achieve it traction within the employer market.
PRODUCTION CAPACITY: 12 million checks monthly.
STRATEGIC DIFFERENCE: In keeping with a report from William Blair analysts Brian Weinstein, Griffin Soriano and Dustin Scaringe: “BD didn’t compete for high-volume, lower-priced contracts and doesn’t have the identical retail presence nationwide that firms like Abbott and Quidel have been capable of safe.”
Cue Well being
TEST: Cue (molecular)
MARKET CAP (ticker: HLTH): $1.1 billion
STOCK PERFORMANCE SINCE SEPTEMBER 2021 IPO: Down 51%
REVENUE: $615 million
FINANCIAL IMPACT OF COVID: All the corporate’s product revenues come from its Covid check.
COMPANY HISTORY: CEO Ayub Khattak, who has a bachelor’s diploma in arithmetic from the College of California, Los Angeles, cofounded the diagnostics testing firm in 2010. Previous to the pandemic, the startup was targeted on analysis. Khattak owns simply over 10.9 million shares, price almost $90 million.
WHAT THEY’VE DONE: Signed contracts with Google, Salesforce and the NBA, plus the Division of Protection. Google began utilizing Cue’s at-home checks for workers final April and is reported to be the corporate’s largest private-sector customer.
Detect
TEST: Detect (molecular)
VENTURE FUNDS RAISED: $110 million.
FINANCIAL IMPACT OF COVID: Detect’s Covid-19 checks are its first and, to this point solely, industrial product.
COMPANY HISTORY: On March 7, 2020, scientist and serial entrepreneur Jonathan Rothberg wrote on Twitter “Fascinated about a low price simple to fabricate house check equipment for #Coronavirus.” The check he designed acquired FDA authorization in October 2021.
WHAT THEY’VE DONE: Made at-home molecular checks cheaper. Detect’s reusable hub, required to start out utilizing its checks, prices $39 in comparison with $249 for Cue’s reader.
WHAT THEY PLAN TO DO: Quickly enhance manufacturing of its Covid check, which turned commercially obtainable in December, to thousands and thousands monthly.
CURRENT STATUS FOR RETAIL CONSUMERS: Bought out.
FUN FACT: In prior lives, CEO Hugo Barra was vp of digital actuality at Fb and vp of Google’s Android division.
KEY QUOTE: “It’s not like we’re going to overlook about house testing as quickly as we go into the endemic part of Covid,” Barra says.
iHealth Labs
See story above.
OraSure Applied sciences
TEST: InteliSwab (antigen)
Market cap (ticker: OSUR): $492 million
PANDEMIC STOCK PERFORMANCE: Up 15%
REVENUE: $234 million
FINANCIAL IMPACT OF COVID: The Inteliswab checks introduced in $22 million in income final yr, beneath the $30 million steerage it had offered to analysts.
WHAT THEY’VE DONE: OraSure gained authorities contracts price greater than $300 million however has struggled to provide checks. The corporate restructured on the finish of 2021 and employed an operations consulting agency utilized by the NIH’s Fast Acceleration of Diagnostics, or RadX, initiative to get manufacturing on monitor.
AN ANALYST’S TAKE: J.P. Morgan’s Tycho Peterson wrote in January that the corporate’s InteliSwab antigen check “has been stricken by delays in FDA approval, in addition to notable manufacturing scale-up points throughout launch.”
THE OUTLOOK: OraSure introduced in January that it was exploring “strategic options,” corporate-speak for a possible sale. It additionally mentioned its CEO Stephen Tang would depart on the finish of March. A brand new CEO has not but been named.
Quidel
TEST: QuickVue (antigen)
MARKET CAP (ticker: QDEL): $4.1 billion
PANDEMIC STOCK PERFORMANCE: Up 11%
TOTAL REVENUE: $1.7 billion
FINANCIAL IMPACT OF COVID: Gross sales of Covid-19 merchandise accounted for 75% of complete income in 2021, or $1.3 billion, up 42% from $891 million the earlier yr. Quidel makes Covid-19 checks utilized by physician’s workplaces in addition to house checks.
WHAT THEY’VE DONE: Acquired a 12-month contract with the U.S. authorities price greater than $500 million, and entered partnerships with CVS, Walgreen, McKesson and the NIH. Bought some 65 million QuickVue at-home Covid checks within the fourth quarter of 2021.
WHAT THEY PLAN TO DO: The corporate has been working to extend manufacturing to 70 million checks monthly.
THE BIG DEAL: Quidel agreed to accumulate Ortho Scientific Diagnostics, an in-vitro diagnostics firm, for about $6 billion, in December 2021.
Siemens Healthineers
TEST: Clinitest (antigen)
MARKET CAP (ADR: SMMNY): $65 billion
PANDEMIC STOCK PERFORMANCE: Up 56%
REVENUE: $21 billion
FINANCIAL IMPACT OF COVID: Income of almost $360 million from fast Covid-19 checks within the final three months of 2021. Upped its steerage for fiscal 2022 (ends Sept. 30) primarily based on projections that its diagnostics division, which incorporates these checks, will deliver in additional than $760 million.
WHAT THEY’VE DONE: The German medical machine maker was one the final entrants to the U.S. house Covid testing market, receiving FDA authorization on the tail finish of 2021.
WHAT THEY PLAN TO DO: Dedicated to creating 50 million checks obtainable by late-March as a part of the Biden Administration’s rollout of 1 billion free checks; additionally slated to ship 84 million checks to the Division of Protection by summer season.
Sources: firms, SEC filings, analyst reviews, J.P. Morgan well being care convention displays, Morningstar, Forbes analysis.
Notes: Complete income is for the 2021 calendar yr no matter fiscal yr; Cue Well being income is preliminary and represents common of $613 million to $618 million vary. Inventory costs and alternate charges as of March 11, 2022. Pandemic inventory efficiency is since March 11, 2020.
MORE FROM FORBES
